Beta Blocker therapy: Evidence from randomized controlled trials' What strategy do we have to choose

1
Beta Blocker therapy Evidence from randomized
controlled trials. What strategy do we have to
choose in the daily practice?

• Mariell Jessup MD
• Professor of Medicine
• University of Pennsylvania
• Philadelphia, Pennsylvania

2
There are many beta-blockers with different
selectivity
Reiter MJ. Prog Cardiovasc Dis 20044711
3
There are many beta-blockers with various
pharmacokinetic profiles.
Reiter MJ. Prog Cardiovasc Dis 20044711
4
Beta-blockers for acute myocardial infarction.
Task Force on Beta-blockers of the European
Society of Cardiology European Heart J
2004251341
5
Beta-blockers as secondary prevention after
myocardial infarction.
Task Force on Beta-blockers of the European
Society of Cardiology European Heart J
2004251341
6
Beta-blockers in chronic heart failure
Task Force on Beta-blockers of the European
Society of Cardiology European Heart J
2004251341
7
Heart Failure trials
Reiter MJ. Prog Cardiovasc Dis 20044711
8
Metoprolol CR/XL Bisoprolol Carvedilol
Bauman et al. J Cardiovasc Pharmacol Therapeut
20049117
9
Task Force on Beta-blockers of the European
Society of Cardiology European Heart J
2004251341
10
Hypertension
Bryan Williams. JACC 200545813
11
Hypertension as a risk.
Bryan Williams. JACC 200545813
12
IMPLICATIONS FOR MODERN TREATMENT TARGETING CVD
RISK RATHER THAN HYPERTENSION? The key debate
over the next few years will not be whether one
class of blood pressure-lowering drug is better
than another, but rather what is the most
effective therapeutic strategy to reduce the
overall CVD risk burden of individual patients.
Bryan Williams. JACC 200545813